Obesity drug supply-demand imbalance is working in Novo Nordisk’s favor: Mizuho’s Jared Holz

February 1, 2024
Obesity drug supply-demand imbalance is working in Novo Nordisk’s favor: Mizuho’s Jared HolzObesity drug supply-demand imbalance is working in Novo Nordisk’s favor: Mizuho’s Jared Holz

Jared Holz, Mizuho Securities, joins ‘Fast Money’ to talk demand in the obesity drug space and who is benefiting from the supply-demand imbalance.

Share This

Latest Mizuho News

See all news
OpenAI vs. Anthropic: the IPO battle that could define the future of AI investing

OpenAI vs. Anthropic: the IPO battle that could define the future of AI investing

April 1, 2026
Biopharma thesis starting to move away from obesity drugs, says Mizuho’s Jared Holz

Biopharma thesis starting to move away from obesity drugs, says Mizuho’s Jared Holz

March 20, 2026
Mizuho Securities Analyst on Latest with Oil and Gas Amid Middle East Conflict

Mizuho Securities Analyst on Latest with Oil and Gas Amid Middle East Conflict

March 13, 2026

Mizuho news from around the globe

 Mizuho Global News
back-to-top-blue